• Human Fc␥RI can trigger antibody-induced inflammatory arthritis, thrombocytopenia, airway inflammation, and systemic anaphylaxis.
• Human Fc␥RI can trigger antibody-induced inflammatory arthritis, thrombocytopenia, airway inflammation, and systemic anaphylaxis.
• Human Fc␥RI can trigger antibody-mediated immunotherapy of mouse metastatic melanoma.
Introduction
Receptors for the Fc portion of IgG (Fc␥Rs) are expressed in humans and mice and mediate most biologic activities of IgG antibodies. Fc␥RI (CD64), Fc␥RIIB (CD32B), and Fc␥RIIIA (CD16A) exist in both species. Fc␥RIIA (CD32A), Fc␥RIIC (CD32C), and Fc␥RIIIB (CD16B) are specific to humans, whereas Fc␥RIV is specific to mice. This nomenclature is based on amino acid sequence homology, but does not systematically reflect functional homologies or similar expression patterns between Fc␥Rs in both species. 1 Therefore, the role of human Fc␥Rs may not be predicted from the role of their homologs studied in mice. Transgenic mice expressing human Fc␥Rs (hFc␥Rs) have been generated to enable their analysis in disease and therapy models in vivo. Whereas hFc␥RIIA has been extensively studied using transgenic mice, [2] [3] [4] [5] some hFc␥Rs, such as hFc␥RI, have been intriguingly understudied in vivo. hFc␥RI is the only high-affinity IgG receptor in humans. It binds human IgG1, IgG3, and IgG4 with a high affinity and has no affinity for IgG2. 6 High-affinity Fc␥Rs (K A ϳ 10 7 -10 8 M Ϫ1 for IgG), but not low-affinity Fc␥Rs (K A ϳ 10 5 -10 6 M Ϫ1 for IgG), are defined by their ability to bind IgG as monomers. Both types of FcRs bind IgG when present in immune complexes (ICs) or when opsonizing cells or surfaces. Therefore, high-affinity Fc␥Rs are thought to be occupied/saturated by IgG in vivo, leading to the belief that prebound IgG prevents the participation of high-affinity receptors in IC-mediated reactions. Inversely, low-affinity Fc␥Rs are believed to remain free and thus to be responsible for IC-mediated reactions. ICs, however, have been reported to displace monomeric IgG from high-affinity Fc␥Rs within minutes. 7 Furthermore, even when in the presence of elevated IgG levels in vitro, high-affinity Fc␥Rs have been reported to retain their ability to bind opsonized RBCs. 8 It could thus be demonstrated that the mouse high-affinity IgG receptor mFc␥RI contributes to inflammation severity in multiple models of disease. [9] [10] [11] [12] [13] [14] The expression pattern of mFc␥RI has been a recent matter of debate. Expression on monocytes and on thioglycolate-elicited macrophages have been reported by some 10, 11, 15 and contradicted by others, 16, 17 whereas all report expression on BM-derived macrophages and no expression on neutrophils. Low levels of Fc␥RI have been reported on dendritic cells (DCs) from normal thymi, with higher levels in the spleen, lymph nodes, and skin-emigrant DCs, 16 and on CD11b ϩ CD11c ϩ MHCII ϩ Ly6C ϩ monocyte-derived skin DCs. 18 However, the cells responsible for the contribution of mFc␥RI to disease models remain to be identified. No role for mFc␥RI could, however, be identified in the passive model of antibody-induced inflammatory arthritis (K/BxN), 19 antibody-induced immune thrombocytopenia, 20 or active systemic anaphylaxis (ASA). 21 It could nevertheless be demonstrated that the other mouse high-affinity IgG receptor, mFc␥RIV, which is expressed on monocyte/ macrophages and neutrophils, contributes to several of these models of autoimmunity, inflammation, and anaphylaxis. 17, 21, 22 The human homolog of mFc␥RI, hFc␥RI, is expressed on blood monocytes and tissue macrophages. 23, 24 Under many circumstances, including chemotherapy, multiple myeloma, 25 rheumatoid arthritis, 23 bacterial infection, sepsis, inflammatory bowel disease, or treatment with recombinant G-CSF, hFc␥RI is also expressed by neutrophils. Therefore, the expression pattern of hFc␥RI and mFc␥RI appear to be different, suggesting that their roles in pathology and therapy may also be very different. Whereas a role for hFc␥RI on DCs has been reported in enhancement of antigen presentation and cross-presentation, 24 its role(s) on monocytes, macrophages, and neutrophils has not been addressed. Monocytes/ macrophages have been involved in IC-induced airway inflammation, 26 in antibody-dependent cellular cytotoxicity of opsonized platelets leading to thrombocytopenia, 15 and of opsonized tumor cells in mouse models of metastatic cancer. 12 Monocytes/ macrophages also induce neutrophil recruitment into inflamed tissue such as joints or pulmonary tissues in models of inflammatory arthritis 27 or airway inflammation, 28 respectively. Neutrophils have been reported to be mandatory for the induction of inflammatory arthritis 29 and IC-dependent airway inflammation and, recently, to contribute to models of systemic anaphylaxis. 2, 21 Mice transgenic for the Fcgr1a gene that recapitulate the expression of the high-affinity receptor hFc␥RI in humans have been generated. 1, 30 Based on its expression pattern, we hypothesized that hFc␥RI may be capable of inducing antibody-dependent autoimmunity, anaphylaxis, and tumor immunotherapy models to which monocytes/macrophages and/or neutrophils have been reported to contribute. We crossed hFc␥RI tg mice with mice deficient for multiple endogenous FcRs and found that hFc␥RI bound several mouse IgG subclasses as monomers, thereby conserving its properties as a high-affinity receptor in vivo in these mice. In this context, we demonstrate that hFc␥RI was sufficient to induce not only autoimmune arthritis, thrombocytopenia, airway inflammation, and fatal systemic anaphylaxis, but could also mediate the therapeutic efficacy of clinically adapted humanized antitumor antibodies on metastatic melanoma. Therefore, the human highaffinity IgG receptor hFc␥RI might be a pro-inflammatory and pro-anaphylactic IgG receptor in humans that can mediate IgGbased antitumor immunotherapies.
Methods

Flow cytometric analysis
Blood cell populations were defined as follows: mouse B cells (CD19 ϩ ), T cells (CD3 ϩ ), monocytes/macrophages (blood/peritoneum: CD11b ϩ / Gr1 Ϫ ; BAL: CD11c ϩ /Gr1 Ϫ ), neutrophils (Gr1 ϩ /SiglecF Ϫ ), basophils (IgE ϩ / DX5 ϩ ), eosinophils (Gr1 int /SiglecF ϩ ), mast cells (IgE ϩ /CD117 ϩ ), platelets (DX5 ϩ /CD61 ϩ ), and natural killer (NK) cells (NK1.1 ϩ /DX5 ϩ ); human B cells (CD19 ϩ ), T cells (CD3 ϩ ), NK cells (CD56 ϩ ), monocytes (CD14 ϩ ) neutrophils (CD24 ϩ ), basophils (CD123 ϩ /CD203c ϩ ), and eosinophils (CD24 ϩ /CD193 ϩ ). Expression of different Flag-tagged FcRs in CHO-K1 cells was compared using anti-FLAG antibody.
IC binding. CHO-K1 cells were incubated with preformed ICs made of 10 g/mL of TNP 5 -BSA-biotin and 15 g/mL of anti-TNP mAbs, for 1 hour at 4°C. Bound ICs were detected using PE-conjugated neutravidin at 2 g/mL for 30 minutes at 4°C.
Monomeric Ig-binding assays. CHO-K1 cells were incubated with 10g/mL monomeric mIgG or rabbit IgG for 1 h at 4°C. Cell-bound Ig was detected using 5g/mL PE-labeled F(abЈ) 2 fragments of antimouse F(abЈ) 2 -specific or 15 g/mL FITC-conjugated F(abЈ) 2 anti-rabbit Ig, respectively, for 30 minutes at 4°C.
Airway inflammation
Mice were injected intranasally with 20 L of rabbit anti-ovalbumin (anti-OVA) antiserum and intravenously with 500 g of OVA. After 18 hours, mice were lethally anesthetized and 4 bronchoalveolar lavages (BALs) of, respectively 0.5, 1, 1, and 1 mL of PBS were performed. The supernatant of the first BAL was used to quantify myeloperoxidase content. The cells from all BALs were pooled for cell-count analysis. Hemorrhage was determined in the cell-free supernatant of pooled BALs after RBC lysis by optical density measurement (570 nm).
Anaphylaxis
PSA.
For the passive systemic anaphylaxis (PSA) assay, ICs made of 80 g of glucose-6-phosphate isomerase (GPI) and 200 L of anti-GPIcontaining serum (K/BxN serum) in 300 L of physiologic solution were performed at 37°C and injected intravenously. Alternatively, 10-200 g of antagonistic blocking anti-hFc␥RI.1 or agonistic nonblocking antihFc␥RI.2 mAb was injected intravenously. Central body temperature was recorded using a digital thermometer (YSI).
ASA. For the ASA assay, mice were injected intraperitoneally on day 0 with 200 g of BSA in complete Freund adjuvant and boosted intraperitoneally on days 14 and 28 with 200 g of BSA in incomplete Freund adjuvant. BSA-specific IgG1, IgG2a/b/c and IgE antibodies in serum were titered by ELISA on day 30 as described previously. 21 Mice with comparable antibody titers were challenged intravenously with 500 g of BSA 8 days after the last immunization. Central temperature was monitored.
Lung metastases model
B16-Luc2 ϩ cells (1 ϫ 10 6 ) were injected intravenously on day 0, and anti-TYRP-1 mAbs TA99 (200 g), CTA99 (500 g), or human IgG1 anti-TYRP-1 (500 g) were injected intraperitoneally on days 0, 1, 2, 4, 7, and 9. Shaved and anesthetized mice were injected intraperitonelly with 3 mg of luciferin 5 minutes before or explanted lungs were exposed to 50 L of 15 mg/mL luciferin 2 minutes before bioluminescence acquisition on an IVIS 100 (Caliper Life Sciences), using 5-minute exposure times with medium binning. Total photon flux (photons/seconds) of the entire lung was calculated using Living Image Version 3.2 software.
Please refer to supplemental Methods (available on the Blood Web site; see the Supplemental Materials link at the top of the online article) for information on mice, reagents, in vivo blocking and depletion, K/BxN serum-induced passive arthritis (K/BxN PA), experimental thrombocytopenia (ITP), surface plasmon resonance analysis, and statistical analyses. All mouse protocols were approved by the Animal Care and Use Committees of Paris, Ile de France, France.
Results hFc␥RI can trigger passive inflammatory arthritis
To investigate the pro-inflammatory potential of hFc␥RI in vivo, we crossed mice transgenic for hFc␥RI (hFc␥RI tg ) 30 to mice deficient for 5 endogenous FcRs (Fc␥RI/IIB/III Ϫ/Ϫ Fc⑀RI/II Ϫ/Ϫ mice, also referred to as 5KO mice). 7 These mice still express the FcR␥-chain that is mandatory for hFc␥RI expression and endogenous Fc␥RIV. In hFc␥RI tg 5KO mice, hFc␥RI was expressed in the blood specifically on Ly6C hi and Ly6C lo monocytes; neutrophils; and peritoneal, liver, lung, and alveolar macrophages, but not on peritoneal mast cells ( Figure 1A ), which is consistent with a previous study. 30 The expression pattern of hFc␥RI in hFc␥RI tg 5KO mice therefore mimics its expression pattern in humans, where hFc␥RI is constitutively expressed on monocytes and inducible on neutrophils. Whereas the expression level of hFc␥RI was higher on neutrophils from these mice compared with human neutrophils from 2 different healthy donors, it was similar on mouse monocytes compared with monocytes from healthy donors ( Figure 1B and supplemental Figure 1A ). hFc␥RI bound mouse IgG2a, IgG2b, and IgG3, but not mouse IgG1, either as monomers ( Figure 1C ) or as ICs ( Figure 1D) . Moreover, the analysis of the interaction of hFc␥RI with mouse IgG2a or with human IgG1 resulted in similar association (k on ) and dissociation (k off ) rate constants, and therefore in a very similar calculated affinity constant (K D ϳ 40nM, ie, K A ϳ 2.5 ϫ 10 7 M Ϫ1 ; Figure 1E -F and supplemental Figure 1B ). Therefore, hFc␥RI retained its properties as a high-affinity receptor for IgG when expressed in transgenic mice.
Because hFc␥RI has been reported to be expressed in the articular synovium of arthritis patients, but not in healthy controls, 31 we investigated whether hFc␥RI could induce arthritic inflammation using hFc␥RI tg 5KO mice and K/BxN serum. The serum of spontaneously arthritic K/BxN mice (F1 offsprings from KRN tg mice crossed with NOD mice) indeed contained pathogenic IgG1 and IgG2 anti-GPI antibodies 17 that were able to form ICs with GPI deposited on the articular cartilage. These ICs induce inflammatory arthritis that requires activating Fc␥Rs. 19 Both 5KO and hFc␥RI tg 5KO mice developed arthritis ( Figure 2A ) after K/BxN serum injection (K/BxN PA). Blocking Fc␥RIV using blocking anti-Fc␥RIV mAbs abolished arthritis in 5KO, but not in hFc␥RI tg 5KO mice. Blocking Fc␥RIV using anti-Fc␥RIV mAbs and hFc␥RI using blocking anti-hFc␥RI.1 mAbs (supplemental Figure 1C ) was necessary to abolish K/BxN PA in hFc␥RI tg 5KO mice ( Figure 2A ). Blocking hFc␥RI significantly reduced arthritis symptoms in hFc␥RI tg 5KO mice ( Figure 2B ). hFc␥RI-dependent arthritis (ie, arthritis developing in anti-Fc␥RIV-treated hFc␥RI tg 5KO mice) was milder than arthritis developing in untreated hFc␥RI tg 5KO mice. Occupancy of a proportion of this human high-affinity receptor by endogenous mouse IgG may be responsible for these mild arthritic symptoms. hFc␥RI-dependent arthritis did not, however, increase in severity when induced in RAGdeficient hFc␥RI tg 5KO mice that lack endogenous IgG ( Figure  2C ). Similar results were obtained for Fc␥RIV-dependent arthritis ( Figure 2C inset). If occurring in vivo, partial occupancy or saturation of hFc␥RI (or Fc␥RIV) by IgG therefore does not affect K/BxN arthritis induction and development. As expected, IgG2 antibodies purified from K/BxN serum induced hFc␥RI-dependent arthritis, whereas IgG1 antibodies purified from K/BxN serum induced only very modest pathologic symptoms ( Figure 2D ). Finally, hFc␥RI-dependent arthritis was abolished when monocytes/ macrophages or neutrophils were depleted ( Figure 2E ). These results demonstrate that hFc␥RI is sufficient to induce K/BxN passive arthritis that is mediated by mouse IgG2 autoantibodies and requires both monocytes/macrophages and neutrophils.
hFc␥RI can trigger antibody-dependent airway inflammation
We next investigated whether hFc␥RI could induce lung inflammation in a model of IC-mediated airway inflammation 28 because hFc␥RI is expressed on lung and alveolar macrophages from hFc␥RI tg 5KO mice ( Figure 1A ). This disease model of a reverse Arthus reaction consists of an IV injection of antigen (OVA) and intranasal instillation of anti-OVA antibodies and was shown to depend on the expression of activating FcRs on alveolar macrophages. 26 IV injection of OVA followed by intranasal instillation of rabbit anti-OVA serum (hFc␥RI binds rabbit IgG, supplemental Figure  1D ) led to a massive infiltration of neutrophils in the airways within 18 hours, as determined in BALs. Whereas blocking either hFc␥RI or mFc␥RIV significantly inhibited neutrophil infiltration, blocking both hFc␥RI and Fc␥RIV was necessary to abolish neutrophil infiltration ( Figure 3A-B) . No major variations in alveolar macrophage numbers under these different conditions were observed ( Figure 3C ), as expected. 28 However, when they did occur, neutrophil infiltration drastically modified the alveolar macrophage/ neutrophil ratio in the BAL ( Figure 3D vs B) . Similarly, whereas myeloperoxidase production in the BAL ( Figure 3E ) resulting from neutrophil and/or macrophage activation and hemorrhage ( Figure  3F ) resulting from tissue damage had a trend of being reduced after hFc␥RI blockade and was significantly reduced after mFc␥RIV blockade, both symptoms were abolished after blockage of both receptors. These results demonstrate that hFc␥RI is sufficient to induce airway inflammation. 
hFc␥RI can trigger PSA
We reported recently that Fc␥RIV was responsible for IgG2b-induced PSA 21 that arises after IV injection of preformed ICs made of mouse IgG2b (anti-DNP) and antigen (DNP-BSA). We therefore investigated the potential of hFc␥RI, which has the same expression pattern and ligands as Fc␥RIV in transgenic mice, to induce PSA in hFc␥RI tg 5KO mice using divalent (anti-hFc␥RI mAbs) or multivalent (IgG-IC) ligands. An IV injection of the nonblocking anti-hFc␥RI.2 mAb, but not of the blocking antihFc␥RI.1 mAb (supplemental Figure 1C) , induced a significant temperature decrease in hFc␥RI tg 5KO mice, but not in 5KO mice ( Figure 4A ). The effect of nonblocking anti-hFc␥RI.2 mAb injections on the central temperature of hFc␥RI tg 5KO mice was dose dependent ( Figure 4B ) and resulted in fatal anaphylactic shocks at higher doses (data not shown). Therefore, whereas anti-hFc␥RI.1 mAb is an antagonistic blocking antibody, anti-hFc␥RI.2 mAb is an agonistic nonblocking antibody capable of inducing hFc␥RI-dependent anaphylaxis. In all further experiments, the in vivo hFc␥RI blockade was achieved by anti-hFc␥RI.1 mAb injections. An IV injection of mouse IgG2b-ICs induced a temperature decrease in 5KO and hFc␥RI tg 5KO mice that was abolished by Fc␥RIV blockade in 5KO mice, as expected, 21 but not in hFc␥RI tg 5KO mice ( Figure 4C ). Confirming the anaphylactogenic potential of hFc␥RI, blocking hFc␥RI reduced the temperature decrease in hFc␥RI tg 5KO mice, and hFc␥RI-dependent PSA (anaphylaxis developing in anti-Fc␥RIV-treated hFc␥RI tg 5KO mice) was abrogated by hFc␥RI blockade ( Figure 4D ). These results demonstrate that hFc␥RI is sufficient to trigger PSA in transgenic mice.
Neutrophils and PAF mediate hFc␥RI-dependent ASA
Because hFc␥RI was sufficient to trigger PSA, we investigated whether hFc␥RI may also trigger ASA. ASA was induced by an IV antigen (BSA) challenge in mice repeatedly immunized with the same antigen in Freund adjuvant (first immunization in complete and second and third immunizations in incomplete Freund adjuvant). This protocol induced a strong body temperature decrease in hFc␥RI tg 5KO mice, but not in 5KO mice, when pretreated with anti-Fc␥RIV mAbs ( Figure 5A ). We called this hFc␥RI-dependent ASA. Supporting this result, hFc␥RI blockade significantly inhibited the ASA-induced temperature decrease ( Figure 5B ) and abolished ASA-induced mortality (supplemental Figure 2A) in hFc␥RI tg 5KO mice. Blocking both hFc␥RI and Fc␥RIV further inhibited ASA-induced temperature decreases in these mice (Figure 5B) . Therefore, hFc␥RI is sufficient to trigger ASA in transgenic mice.
Both effector cell types that express hFc␥RI, monocytes/ macrophages 32 and neutrophils, 21 can potentially contribute to ASA. hFc␥RI-dependent ASA was strongly inhibited by neutrophil depletion after injection of anti-Gr1 mAbs ( Figure 5C ). Because this rat IgG2b anti-Gr1 mAb injection may lead to activation and depletion of complement components due to in vivo IC formation, as suggested previously, 33 we investigated whether the inhibition of hFc␥RI-mediated active anaphylaxis after anti-Gr1 mAb treatment relied on complement. A dose of cobra venom factor (CVF) that inactivates both C3 and C5 components of the complement 34 did neither prevent hFc␥RI-mediated active anaphylaxis nor its inhibition after anti-Gr1 mAb injections (supplemental Figure 2B) . Therefore, the inhibition of anaphylaxis after anti-Gr1 mAb injection is dependent on neutrophil depletion per se and not on complement. Surprisingly, neither monocyte/macrophage depletion after toxic liposome injection ( Figure 5D ) nor inhibition of monocyte/macrophage function after gadolinium injection ( Figure  5E ) reduced hFc␥RI-dependent ASA. Unexpectedly, the injection of toxic liposomes or gadolinium increased hFc␥RI-induced hypothermia. However, the depletion or inhibition of monocytes/ BLOOD, 28 FEBRURY 2013 ⅐ VOLUME 121, NUMBER 9 For personal use only. on October 28, 2017. by guest www.bloodjournal.org From macrophages, when combined with the depletion of neutrophils, had a tendency to increase the protection from hFc␥RI-dependent ASA ( Figure 5D -E). Neutrophils and, possibly to a minor extent, monocytes/macrophages therefore contribute to hFc␥RI-dependent ASA. Mediators released and/or secreted by these activated cell types should therefore be responsible for the anaphylactic shock observed. Among them, platelet activating factor (PAF) was shown to be responsible for neutrophil-dependent ASA 21 and for macrophage-dependent ASA, 32 whereas histamine was shown to be responsible for mast cell-dependent anaphylaxis. 35 The PAF-R antagonist ABT-491, but not the histamine and serotonin receptor antagonist cyproheptadine, markedly reduced hFc␥RI-dependent temperature decrease ( Figure 5F ) and mortality (supplemental Figure 2C ). PAF therefore accounts for hFc␥RI-dependent ASA. However, the conjunction of both antagonists further reduced hFc␥RI-dependent ASA ( Figure 5F ). In addition to mast cells and basophils, neutrophils have been reported to be able to release histamine 36 but not serotonin, suggesting that histamine released by neutrophils might, to a minor extent, contribute to hFc␥RI-dependent ASA.
Monocytes/macrophages mediate hFc␥RI-dependent thrombocytopenia
We next investigated whether, in addition to exerting proinflammatory and pro-anaphylactic properties, hFc␥RI may also exert phagocytic properties in vivo using a murine model of thrombocytopenia. Immune thrombocytopenic purpura (ITP) can be induced by injecting IV antiplatelet antibodies (reminiscent of autoantibodies found in ITP patients) and by monitoring circulating platelet consumption. ITP could be induced after injection of mouse IgG2a antiplatelet mAbs both in hFc␥RI tg 5KO mice and in 5KO mice. Fc␥RIV blockade prevented ITP in 5KO mice (as expected based on previous findings 21, 22 ), but reduced platelet consumption by less than 50% in hFc␥RI tg 5KO mice ( Figure  6A-B) . The remaining platelet consumption was hFc␥RI dependent, because it was prevented by a further hFc␥RI blockade ( Figure 6B ). hFc␥RI-dependent ITP was not affected by neutrophil depletion ( Figure 6C ), but was significantly inhibited by monocyte/ macrophage depletion ( Figure 6D ). Splenectomy had no significant effect on hFc␥RI-dependent ITP ( Figure 6E ), suggesting that hFc␥RI-expressing macrophages other than splenic macrophages contribute to platelet clearance in this model. Liver macrophages (ie, Kupffer cells), which belong to the mononuclear phagocyte system, express hFc␥RI in hFc␥RI tg 5KO mice ( Figure 1A) , could be responsible for platelet consumption in this model.
hFc␥RI can mediate Ab-induced antitumor immunotherapy
Because hFc␥RI can mediate Ab-induced platelet clearance, we investigated whether hFc␥RI may also mediate tumor reduction/ destruction after antitumor Ab injection. We used the B16 melanoma (expressing gp75 aka TYRP-1) tumor immunotherapy model that relies on injections of anti-TYRP-1 mouse IgG2a TA99 mAb and that was reported to involve the contribution of the mouse homolog mFc␥RI 12,37,38 of hFc␥RI. To allow accurate quantification of lung metastases (ie, tumor load) after IV injection of the tumor, we used a luciferase-expressing variant of B16 (B16 luc2 ϩ ) that expresses similar amounts of TYRP-1 as wild-type (wt) B16 cells (supplemental Figure 3A) . IV injections of B16 wt or B16 luc2 ϩ cells in wt C57BL/6J mice led to metastatic melanoma in the lung that could be quantified by bioluminescence imaging on explanted lungs ex vivo in the case of B16 luc2 ϩ -injected mice (supplemental Figure 3B) . Repeated TA99 injections lead to a drastic reduction in tumor load in wt C57BL/6J mice, but not in FcR␥ Ϫ/Ϫ mice that lack all activating FcRs ( Figure 7A ) or in 5KO mice ( Figure 7B ). However, TA99 injections did lead to a significant reduction in tumor load in hFc␥RI tg 5KO mice ( Figure  7B ). Therefore, hFc␥RI can mediate metastatic melanoma reduction after mouse IgG2a anti-TYRP-1 mAb injections.
A chimeric version of TA99 with a human IgG1 heavy chain (CTA99; developed by Imclone, US patent 2009/0232823 A1) has been constructed to test the therapeutic efficacy of this mAb in clinical trials. Heat aggregates of CTA99 (or human polyclonal IgG1) mimicking ICs readily bound hFc␥RI in vitro (supplemental Figure 3C ). CTA99 injections led to a significant reduction in tumor load in hFc␥RI tg 5KO mice pretreated with anti-Fc␥RIV mAbs that was abolished by hFc␥RI blockade ( Figure 7C) . A significant reduction in tumor load after CTA99 injection and an abolition of this effect after hFc␥RI blockade were also obtained in anti-Fc␥RIV mAb pretreated RAG-deficient hFc␥RI tg 5KO mice that cannot produce endogenous antibodies ( Figure 7D ). Furthermore, injections of a fully human IgG1 mAb anti-TYRP-1 39 had a tendency to reduce tumor loads in hFc␥RI tg 5KO mice pretreated with anti-Fc␥RIV mAbs ( Figure 7E ). Therefore, hFc␥RI mediates Ab-induced reduction of tumor load in transgenic mice after injection of humanized anti-TYRP-1 mAbs. 
Discussion
The results of the present study suggest that although hFc␥RI is characterized as a high-affinity receptor for IgG, hFc␥RI is readily available in vivo to bind IgG-ICs or IgG-opsonized targets. Despite its potential saturation by IgG in vivo, hFc␥RI was indeed sufficient to mediate pro-inflammatory, pro-anaphylactic, and antitumor functions, leading to autoimmune, allergic, and therapeutic reactions, respectively, in transgenic mice. Neutrophils contributed predominantly to hFc␥RI-induced anaphylaxis, whereas monocytes/ macrophages contributed predominantly to hFc␥RI-induced autoimmune thrombocytopenia. Both neutrophils and monocytes/ macrophages were, however, required for hFc␥RI-induced autoimmune arthritis, demonstrating their nonredundant roles in this arthritis model. hFc␥RI-expressing resident macrophages may attract circulating hFc␥RI-expressing neutrophils that are responsible for inflammation and cartilage destruction in this arthritis model, as suggested from studies using wt mice. 27, 29 To investigate the role of human Fc␥RI in vivo, we used transgenic mice for this receptor 30 that display an expression pattern of hFc␥RI comparable to that found in humans. Monocytes, macrophages, and DCs in humans and in these transgenic mice indeed express hFc␥RI. However, hFc␥RI was reported to be inducible on human neutrophils, whereas neutrophils from hFc␥RI tg mice constitutively express hFc␥RI. Nevertheless, hFc␥RI was reported to be expressed on human neutrophils under multiple circumstances, including in particular rheumatoid arthritis 23 and multiple myeloma. 25 One can therefore consider that human neutrophils may express hFc␥RI in most inflammatory contexts. To avoid a possible in vivo competition or contribution of endogenous Fc␥Rs to reactions mediated by hFc␥RI, we crossed hFc␥RI-transgenic mice with 5KO mice that lack Fc␥RI, Fc␥RIIB, Fc␥RIII, Fc⑀RI, and Fc⑀RII. 7 The resulting hFc␥RI tg 5KO mice express only 2 activating FcRs, transgenic hFc␥RI and endogenous Fc␥RIV, which could be efficiently blocked in vivo to study the specific contribution of hFc␥RI to a particular disease or therapy model. The expression of the transgene in this background led to an increased expression level of hFc␥RI on neutrophils in transgenic mice compared with humans, but a very similar expression on monocytes. Testing anti-hFc␥RI-specific mAbs in vivo in these mice revealed an agonist/nonblocking activity (anti-hFc␥RI.2 mAb) or an antagonist/blocking activity (anti-hFc␥RI.1 mAb). hFc␥RI bound not only human IgG1/3/4 subclasses, 6 but also mouse IgG2a/2b subclasses as monomers. The affinity of hFc␥RI for mIgG2a was very similar to its affinity for hIgG1 (K D ϳ 38nM and 40nM, respectively), in the range of the high-affinity mIgG2a-mFc␥RIV interaction (K D ϳ 34nM). 22 Therefore, hFc␥RI functions as a high-affinity IgG receptor not only in humans, but also in hFc␥RI tg mice. The fact that hFc␥RI conserved its high-affinity properties for mouse IgG validates hFc␥RI tg mice as a model with which to study the contribution of hFc␥RI to disease and therapy.
In hFc␥RI tg mice, we found that the engagement of hFc␥RI alone or of Fc␥RIV alone resulted in reactions with a lower intensity than the engagement of both receptors. Because hFc␥RI and Fc␥RIV associate with the same FcR␥-subunit to mediate signal transduction, their aggregation by ICs should not lead to qualitatively different responses. Insufficient expression levels or occupancy of a proportion of these high-affinity receptors by endogenous (monomeric) IgG2 may, however, explain this phenomenon. The latter possibility, described previously, 40 certainly dissuaded many from investigating the role of hFc␥RI in IgGmediated effector reactions in vivo. In the present study, we demonstrate that hFc␥RI can readily induce inflammatory reactions after passive administration of pathogenic IgG despite its ability to be bound/saturated by endogenous monomeric IgG. In addition, the intensity and kinetics of the responses triggered by hFc␥RI were comparable to those triggered by low-affinity FcRs. Supporting our observations, the mouse high-affinity FcRs Fc␥RI and Fc␥RIV were reported to play similar roles as mouse low-affinity Fc␥RIII in models of inflammation. 19, 21, 28 Finally, we observed no difference in the kinetics of the appearance of hFc␥RI-dependent arthritic symptoms, nor in their severity, between IgG-sufficient (hFc␥RI tg 5KO) and IgG-deficient (RAG-deficient hFc␥RI tg 5KO) mice.
This work and previous studies support the notion that being of high or low affinity for IgG, Fc␥Rs engaged by a given multivalent ligand and expressed by a given cell will induce with comparable kinetics the activation of that cell and consequently in vivo responses. It follows that the ability of high-affinity Fc␥Rs to bind monomeric IgG has no detectable consequence in vivo. One could therefore consider that high-affinity Fc␥Rs remain as unoccupied as low-affinity Fc␥Rs in vivo. Nevertheless, the high concentration of circulating IgG favors the hypothesis that at any given time a proportion of high-affinity, but also low-affinity, Fc␥Rs are interacting with IgG. Low-and high-affinity Fc␥Rs were indeed reported to bind monomeric IgG with a half-life of the interaction varying from less than 1 minute to more than 10 minutes, 7, 20, 22, 41 respectively. Consistent with these previous results, we report herein an approximately 4-minute half-life for the interaction of hFc␥RI with hIgG1 or with mIgG2a. Results obtained in vivo nevertheless suggest that these half-lives are sufficiently short to allow low-and high-affinity Fc␥Rs to rapidly bind IgG-ICs and to induce cell activation.
We found that hFc␥RI can induce several allergy-related reactions in hFc␥RI tg mice. In the model of airway inflammation, hFc␥RI triggered neutrophil infiltration, hemorrhage, and myeloperoxidase production in the alveolar space, symptoms that are reminiscent of those found in asthma patients. Whereas this model has been reported to be macrophage dependent, we could not formally demonstrate the contribution of these cells to hFc␥RI-induced airway inflammation because of inefficient depletion of alveolar macrophages. Nevertheless, the fact that alveolar macrophages represent more than 90%-95% of the cells in the BAL of unchallenged mice and that they express hFc␥RI supports a role for alveolar macrophages in this reaction. hFc␥RI was also able to induce PSA when triggered by divalent or multivalent ligands and by ASA. As with ASA in wt mice, 21 hFc␥RI-induced ASA relied predominantly on neutrophils and PAF. Because hFc␥RI is expressed at higher levels on neutrophils from hFc␥RI tg mice than on those from humans, the contribution of neutrophils might be overestimated in the mouse model we used. The expression of hFc␥RI is, nevertheless, not higher on neutrophils than on monocytes and macrophages in these mice. Surprisingly, whereas monocytes/macrophages were reported to contribute predominantly to human Fc␥RIIA-induced systemic anaphylaxis 2 and to particular models of passive and active anaphylaxis, 32 monocytes/ macrophages did not significantly contribute to anaphylaxis in hFc␥RI tg mice. Whereas it has been reported that hFc␥RI is expressed on in vitro-stimulated human cord blood-derived mast cells, 42 it has not been reported on human skin mast cells 43 or mast cells from hFc␥RI tg mice (present study). Whatever the relative contribution of these cell subsets to allergic and anaphylactic reactions in humans, our results suggest that hFc␥RI may be a key player in allergic and anaphylactic reactions in humans when allergen-specific IgGs are present.
hFc␥RI has been reported to allow antigen targeting to DCs to enhance antigen presentation, 24 and we report herein that hFc␥RI contributes to the induction of several inflammatory models in hFc␥RI tg mice. The mouse homolog of Fc␥RI, mFc␥RI, is also expressed on DC populations, particularly monocyte-derived DCs, 16, 18 and has been reported to play similar roles as hFc␥RI in enhancing antigen presentation of IgG-bound antigen. 11 Whereas the expression of mFc␥RI on circulating monocytes and macrophage subsets is under debate, 10, 11, [15] [16] [17] expression of mFc␥RI could not be detected on neutrophils in steady-state conditions, during inflammatory arthritis, or in tumor-bearing mice (data not shown). The absence of mFc␥RI on these effector cells suggests that one of its main activities may be to favor antigen presentation by and activation of DCs, in agreement with its contributions reported after active immunization protocols. 10, 11 Passive models of disease using mFc␥RI Ϫ/Ϫ mice nevertheless reported an effect of mFc␥RI deficiency in IC-induced Arthus reactions in the footpad 11 and in Ab-induced autoimmune hemolytic anemia. 10,13 mFc␥RI may therefore be a functional homolog of hFc␥RI when considering DCs. When considering neutrophils, however, mFc␥RIV, which does not exist in humans, may be a functional homolog of hFc␥RI. Like hFc␥RI (present study), mFc␥RIV is indeed expressed on these cell subsets 7, 22 and was reported to contribute to anaphylaxis, 21 arthritis, 17 airway inflammation, 26 and thrombocytopenia. 20, 21 We therefore propose that hFc␥RI may recapitulate in humans the roles played in mice by mFc␥RI on DCs to favor antigen presentation and cell activation and by mFc␥RIV on neutrophils to trigger effector (pro-inflammatory) reactions. Whether mFc␥RI and/or mFc␥RIV recapitulates in mice the roles played by hFc␥RI in humans is unclear and will require more investigation, in particular in the expression of mFc␥RI on monocyte/macrophage subpopulations.
The model of B16 metastatic melanoma has been used extensively to study the contribution of FcRs to experimental antibodybased immunotherapy. Using a bioluminescent variant of B16 and either the mouse IgG2a anti-TYRP-1 mAb TA99 or its humanized version CTA99 bearing the constant regions of a human IgG1, we report herein that hFc␥RI can mediate antibody-based immunotherapy. hFc␥RI may thus contribute to (or be responsible for) the reduction of B16 metastatic melanoma recently observed in mice expressing multiple hFc␥Rs injected with a humanized anti-TYRP-1 mAb TA99. 44 Furthermore, we demonstrate in the present study that hFc␥RI could mediate the protective effect of a fully human IgG1 anti-TYRP-1 mAb, which is currently being evaluated in a phase 1 trial involving patients suffering from malignant melanoma. CTA99 and fully human anti-TYRP-1 were, however, less efficient than TA99 in the mouse model of metastatic melanoma. In mice and humans, the neonatal IgG receptor FcRn is responsible for the protection of IgG degradation and contributes to IgG distribution into tissues. 45 The binding of human IgG1 to mouse FcRn is almost 3 times lower than the binding of mouse IgG2a to mouse FcRn. 46 Therefore, the half-life and/or biodistribution of human IgG1 may be reduced compared with that of mouse IgG2a when injected in mice, suggesting a reduced opsonization and elimination of tumor cells. The mechanism by which hFc␥RI mediates the protective effect of anti-TYRP-1 mouse mAb TA99, humanized IgG1 mAb CTA99, and fully human IgG1 mAb on metastatic melanoma remains to be identified, but should not require NK cells because these cells do not express hFc␥RI. However, myeloid cells, macrophages in particular, might be responsible for metastasis reduction in this model. Intriguingly, in the absence of all other Fc␥Rs, mFc␥RIV was not sufficient to mediate TA99-based tumor immunotherapy, whereas its absence (Fc␥RIV Ϫ/Ϫ mice) or in vivo blockade in wt mice (anti-Fc␥RIV mAbs) has been reported to reduce the efficiency of TA99 in this model. 20, 47 The expression of hFc␥RI was sufficient to restore antibody-based tumor immunotherapy in mice that could not mediate this property anymore. This property of hFc␥RI is reminiscent of that found for its mouse homolog mFc␥RI in mediating the protective effects of anti-TYRP-1 mAb TA99 on B16 lung metastases 38 or liver metastases. 37 Most current preclinical studies based on hFc␥RI only exploit its functions in favoring antigen presentation. [48] [49] [50] In addition to these properties, we report in the present study that hFc␥RI can also mediate the protective effects of antitumor antibodies on melanoma metastases and therefore potentially also on solid tumors. Supporting this assumption, bispecific antibodies directed against hFc␥RI and c-erbB-2, a transmembrane receptor highly expressed in several human malignancies, indeed trigger hFc␥RI-dependent antibody-dependent cell cytotoxicity in vitro. [48] [49] [50] We also report herein that hFc␥RI can induce several mouse models of autoimmune and allergic reactions and can therefore be considered a potential pro-inflammatory and pro-anaphylactic activating IgG receptor in humans. Anti-hFc␥RI-blocking mAbs prevented hFc␥RI-dependent models of autoimmunity and allergy and may therefore be assessed for their efficiency in human pathologies. Finally, our results indicate that hFc␥RI, and potentially other high-affinity FcRs, are either not occupied/saturated by IgG in vivo or, if they are, this comes without functional consequences on their ability to mediate antitumor activities and pro-inflammatory and pro-anaphylactic properties.
